NocoCure Shares Are Trading Higher After the Company Announced Its Phase 3 PANOVA-Trial Met Its Primary Endpoint and Demonstrated a Statistically Significant Improvement in Its Median Overall Survival Rate.
NocoCure Shares Are Trading Higher After the Company Announced Its Phase 3 PANOVA-Trial Met Its Primary Endpoint and Demonstrated a Statistically Significant Improvement in Its Median Overall Survival Rate.
NocoCure股票上漲，因爲該公司宣佈其第3階段PANOVA試驗達到了主要終點，並顯示其中位總生存率有統計學顯著改善。
NocoCure Shares Are Trading Higher After the Company Announced Its Phase 3 PANOVA-Trial Met Its Primary Endpoint and Demonstrated a Statistically Significant Improvement in Its Median Overall Survival Rate.
NocoCure的股票在公司宣佈其第三階段PANOVA試驗達到了主要終點並在中位總生存率上顯示出統計學顯著改善後，價格上漲。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
資訊熱榜
更新時間